Cargando…

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis

Background. Recent years have witnessed the advent of molecular profiling for intrahepatic cholangiocarcinoma (iCCA), and new techniques have led to the identification of several molecular alterations. Precision oncology approaches have been widely evaluated and are currently under assessment, as sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizzo, Alessandro, Carloni, Riccardo, Ricci, Angela Dalia, Di Federico, Alessandro, Guven, Deniz Can, Yalcin, Suayib, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410256/ https://www.ncbi.nlm.nih.gov/pubmed/36013199 http://dx.doi.org/10.3390/jpm12081247

Ejemplares similares

Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
por: Carloni, Riccardo, et al.
Publicado: (2022)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
por: Guven, Deniz Can, et al.
Publicado: (2022)

Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma
por: Andrici, Juliana, et al.
Publicado: (2016)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma
por: Marcus, Rebecca, et al.
Publicado: (2021)

Novel Targeted Therapies for Advanced Cholangiocarcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2021)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Prognostic value of integrated morphofunctional imaging methods in inoperable intrahepatic cholangiocarcinoma
por: Nanni, Cristina, et al.
Publicado: (2023)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
por: Rizzo, Alessandro, et al.
Publicado: (2020)

The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
por: Palloni, Andrea, et al.
Publicado: (2023)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma
por: Sabbatino, Francesco, et al.
Publicado: (2020)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways
por: Chen, Xu-Xiao, et al.
Publicado: (2018)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
por: Di Federico, Alessandro, et al.
Publicado: (2022)

Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma
por: Granata, Vincenza, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role
por: De Lorenzo, Stefania, et al.
Publicado: (2020)

Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study
por: Mosconi, Cristina, et al.
Publicado: (2016)

The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma
por: Yu, Hua, et al.
Publicado: (2020)

Correction: Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma
por: Granata, Vincenza, et al.
Publicado: (2022)

Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review
por: Bisello, Silvia, et al.
Publicado: (2021)

Prognostic value of site-specific metastases for patients with advanced intrahepatic cholangiocarcinoma: A SEER database analysis
por: Cheng, Rui, et al.
Publicado: (2019)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link
por: Brandi, Giovanni, et al.
Publicado: (2022)

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
por: Di Marco, Mariacristina, et al.
Publicado: (2020)

Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2023)

Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma
por: Auer, Timo Alexander, et al.
Publicado: (2023)

Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies
por: Acher, Alexandra W., et al.
Publicado: (2021)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ouikjkrgpat1k4qekofpc2nh02